RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$97.71
−1.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$99.36
From 52W high−16.93%
Volume1.05M
Market cap$6.73B
P/E (TTM)—
P/S (TTM)28.0x
Div yield—
Key dataSep 18, 2026
Open
$99.36
From 52W high
−16.93%
Volume
1.05M
Market cap
$6.73B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.3x
P/E (TTM)
—
RSI (14)
35.3
MomentumView details →
1D Return
−1.32%
YTD Return
−9.39%
SummaryUpdated Jun 1, 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in October 2017 and focuses exclusively on developing and commercializing therapeutics for rare genetic diseases of obesity. Rhythm has successfully transitioned from a development-stage company to a commercial enterprise with its flagship product IMCIVREE, which targets specific genetic pathways that control hunger and weight regulation. The company operates in the highly specialized field of rare genetic obesity disorders, serving patients with conditions that were previously considered untreatable.
Similar companies
Latest newsMore news →
Rhythm Pharmaceuticals announced that it and its collaborators will present three posters and three oral presentations on setmelanotide in rare MC4R pathway diseases at the 64th Annual European Society for Paediatric Endocrinology Meeting in Marseille, France, September 8-10, 2026.10d agoRhythm Pharmaceuticals appointed Manher (AJ) Joshi as Chief Medical Officer, effective August 17, 2026.34d ago